Loading clinical trials...
Loading clinical trials...
Phase I/II Safety lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy
Conditions
Interventions
Caspofungin Acetate 50 MG
Physiologic saline
Locations
1
France
CHU Tours
Tours, France
Start Date
June 1, 2025
Primary Completion Date
June 1, 2026
Completion Date
December 1, 2028
Last Updated
March 25, 2025
NCT06691321
NCT06431958
NCT06442345
NCT06173453
NCT05458752
NCT03087890
Lead Sponsor
University Hospital, Tours
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions